Printer Friendly

BIOSOURCE INTERNATIONAL INTRODUCES FAMILY OF MURINE CYTOKINE TEST KITS; ASSAYS FOR STUDYING MOUSE IMMUNOLOGICAL SYSTEMS

 CAMARILLO, Calif., Jan. 12 /PRNewswire/ -- BioSource International Inc. (NASDAQ: BIOI) today announced the immediate availability of five new Cytoscreen(TM) test kits for studying murine (mouse) immunological systems. The new kits are Mouse Interferon-gamma (MIFN-gamma), and four Mouse Interleukin (mIL) kits: mIL-2, mIL-4, mIL-6 and mIL-10.
 All of the products are ELISA kits: quantitative, "sandwich" enzyme-linked, immunoabsorbent assays for the detection of biologically active cytokines from blood serum, plasma and culture supernatant samples. Presence of these cytokines in a sample typically indicates an immune system response, making them useful in the development and study of new drugs for diseases such as AIDS, cancer and other immunological disorders. Murine test kits are used extensively in the pre-clinical research phase of biotechnology product development, and in university and hospital research laboratories.
 "The murine cytokine test kits were developed under the direction of Dr. Madelyn Baran, vice president of product development, and the team of scientists we recruited beginning in the spring of 1993," said James Chamberlain, president and chief executive officer of BioSource. "They met an aggressive development schedule that further validates our strategy of pursuing significant business opportunities based on in-house capabilities and also met the delivery schedule for our first joint development agreement."
 Chamberlain noted that four of the new kits represent fulfillment of a joint development agreement with Bender MedSystems (Vienna, Austria), a wholly owned subsidiary of the Boehringer-Inglehiem Group. BioSource obtained and produced the basic materials and test protocols for the kits, which Bender MedSystems will manufacture and market in Europe, for a fee paid to BioSource. BioSource will manufacture and market the kits in the North American market.
 "We estimate that the overall worldwide market for murine cytokine test kits is about three million dollars annually," said Chamberlain. "The new products, like all our Cytoscreen test kits, offer the added value of two strip-well plates, instead of one, to increase convenience for the researcher. We intend to aggressively market these new entries in our growing line of ELISA kits and expect 1994 revenue from them to reach approximately $500,000."
 BioSource introduced its first internally developed and manufactured Cytoscreen ELISA assay kits in early 1993 and now markets 18 kits, including tests for human interleukin, stem cell factor, interferons and tumor necrosis factor; and a variety of rat, mouse and monkey cytokines. All of BioSource's ELISA assays are shipped with two test plates and all materials needed to test up to 192 samples. For more information, or to order kits, researchers can call 800-242-0607.
 BioSource International Inc. is a Camarillo-based supplier of immunological reagents and test kits used in biomedical research. The company offers more than 600 products, including recombinant proteins, monoclonal antibodies and ELISA assay kits to a variety of antigens. Incorporated in 1989, the company was listed on NASDAQ in May 1993, after completing the acquisition of Tago Inc. Combined FY 1992 revenues of the merged company were $4 million. Revenues in the first nine months of 1993 (Jan. 1-Sept. 30) were $4.06 million, and the company reported net income of $419,021.
 NOTE: Cytoscreen is a trademark of BioSource International Inc.
 -0- 1/12/94
 /CONTACT: James Chamberlain or Anna Anderson, treasurer of BioSource, 805-987-0086; or Matthew Schmidt of FS Communications, 415-691-1488, for BioSource/
 (BIOI)


CO: BioSource International Inc. ST: California IN: MTC SU: PDT

TM-TB -- SJ008 -- 1513 01/12/94 16:00 EST
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 12, 1994
Words:561
Previous Article:GBC TECHNOLOGIES ANNOUNCES ACQUISITION AGREEMENT WITH VISTA TECHNOLOGY
Next Article:CP&L PLANS TO ISSUE FIRST MORTGAGE BONDS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters